Form 4: Lantern Pharma Director Granted 43,460 Stock Options

Lantern Pharma Inc. director Lee Troy Schalop was granted 43,460 stock options at an exercise price of $3.49, vesting over 12 and 24 months.

Summary

• Director Lee Troy Schalop of Lantern Pharma Inc. (LTRN) was granted a total of 43,460 stock options.
• The options were granted on January 9, 2026, with an exercise price of $3.49 per share.
• One tranche of 25,000 options will vest in equal monthly increments over a 24-month period, commencing February 9, 2026.
• A second tranche of 18,460 options will vest in equal monthly increments over a 12-month period, commencing February 9, 2026.
• All options expire on January 8, 2036.
• The grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a neutral to slightly positive event, as it aligns management incentives with shareholder interests, though it introduces potential future dilution. It's a standard compensation practice.

Positives

• The grant of stock options to a director aligns their interests with long-term shareholder value creation.
• Incentivizes the director to remain with the company and contribute to its growth over the vesting periods.

Negatives

• The issuance of new stock options represents potential future dilution for existing shareholders if the options are exercised.

Risks

• Potential future dilution of existing shareholder equity if the granted stock options are exercised.
• The value of the options is dependent on the future stock price exceeding the exercise price of $3.49.

Future Outlook

The stock option grants are intended to incentivize long-term performance and retention of the director, aligning their interests with the company's future success.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain talent in a highly competitive sector. This practice is standard for incentivizing leadership in companies focused on long-term R&D and product development cycles.

Comparison to Industry Standards

• The use of stock options as a compensation tool for directors is a standard practice across the biotechnology and pharmaceutical industries, similar to companies like Amgen or Gilead Sciences, which frequently use equity grants to align management incentives with shareholder value.
• The vesting schedules (12 and 24 months) are typical for director equity grants, designed to encourage sustained commitment and performance over a multi-year horizon, comparable to practices observed at peer companies in the small-cap biotech space.
• An exercise price of $3.49, likely at or above the market price on the grant date, is standard for incentive stock options, ensuring that the options only gain value if the company's stock price appreciates.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential for increased long-term value creation due to incentivized leadership.
• Employees: May signal a stable and incentivized leadership team, potentially boosting morale.

Next Steps

• The options will begin vesting in equal monthly increments starting February 9, 2026.
• The director will be able to exercise vested options at any time before the expiration date of January 8, 2036.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to an existing director as part of their compensation package. While it introduces potential future dilution, it also serves to align the director's interests with long-term shareholder value. Such a standard compensation event typically does not warrant a change in investment recommendation, hence a 'hold' is appropriate, assuming the investor's existing thesis remains intact.

Keywords

Lantern Pharma, LTRN, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Biotechnology, Pharmaceuticals